Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of SC tanezumab in knee OA
NCT01127893Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jun 2010
- Primary completion
- Sep 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tanezumab in osteoarthritis (OA) (3 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 107, Number of Participants With Clinically Significant Laboratory Abnormalities at Day 107 and 4 more. Started Jun 2010; status: terminated.
02
Drugs
tanezumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT01127893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01127893.